Related Experiment Video
Updated: Dec 28, 2025

12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.0K
Frontotemporal dementias: main syndromes and underlying brain changes.
1The University of Sydney, School of Psychology and Brain & Mind Centre, Sydney, Australia.
Current Opinion in Neurology
|February 13, 2020
Summary
Frontotemporal dementia (FTD) is challenging to diagnose due to varied symptoms. This review updates knowledge on FTD syndromes, brain changes, and genetics, highlighting new behavioral insights and genetic factors.
Area of Science:
- Neurology
- Neuroscience
- Genetics
Background:
- Frontotemporal dementia (FTD) is a rare neurodegenerative disorder, comprising approximately 15% of all dementia cases.
- Despite established diagnostic criteria, FTD presents diagnostic challenges due to its complex clinical variability and heterogeneous underlying disorders.
- Recent research highlights the increasing recognition of behavioral changes across all FTD variants, including language-dominant forms.
Purpose of the Study:
- To provide an updated review of the current knowledge on the primary Frontotemporal dementia syndromes: behavioral variant (bvFTD), semantic variant (svFTD), and nonfluent/agrammatic variant (nfvFTD).
- To summarize recent findings regarding the brain abnormalities associated with these FTD subtypes.
- To review the genetic profiles implicated in the etiology of FTD.
Main Methods:
- This review synthesizes current scientific literature and recent research findings on Frontotemporal dementia.
- It integrates clinical observations, neuroimaging data, and genetic studies related to FTD.
- The review focuses on updates concerning the main FTD syndromes and their biological underpinnings.
Main Results:
- The clinical complexity of FTD is increasingly evident, particularly in behavioral changes, which are now recognized across semantic and nonfluent/agrammatic variants.
- Novel pathological subcategories within FTD are continually being identified.
- Genetic analysis reveals that mutations in three specific genes account for nearly 75% of familial FTD cases.
Conclusions:
- Effective pharmacological treatments for FTD are lacking, necessitating the development of novel therapeutic strategies targeting debilitating symptoms like language impairment and behavioral disturbances.
- Emerging interventions show promise but require further validation.
- Continued research into FTD's diverse clinical presentations, biological markers, and genetic factors is crucial for improving diagnosis and treatment.
Related Concept Videos
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Dementia
458
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
458
Parkinson's Disease: Overview
1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Dissociative Disorders
377
Dissociative disorders represent complex psychological conditions characterized by disruptions in consciousness, memory, identity, or perception. These disruptions cause individuals to experience a disconnection from their thoughts, emotions, and memories. The phenomenon is not merely an occasional lapse in attention but a profound alteration in mental functioning that can severely impact daily life.
Dissociative Fugue
A hallmark feature of dissociative disorders is the dissociative fugue...
Dissociative Fugue
A hallmark feature of dissociative disorders is the dissociative fugue...
377
Biological Causes of Schizophrenia
416
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
416
Alzheimer's Disease: Treatment
699
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
699

